Fluzoparib disrupts Golgi apparatus to inhibit O-GlcNAcylation and nuclear translocation of β-catenin to attenuate ovarian cancer invasion and metastasis
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115158 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Jiaxin Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. Hauptthemen laut MEDLINE: Golgi Apparatus, Ovarian Neoplasms, beta Catenin, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Ovarian cancer is one of the most common malignant tumors of the female reproductive system, with the majority of patients already presenting with peritoneal dissemination and other metastases at the time of initial diagnosis. Fluzoparib (FZ) is the first domestically developed PARP inhibitor in China. The efficacy of FZ in inhibiting the invasiveness and metastasis of ovarian cancer remains uncertain, and its potential mechanisms are yet to be elucidated. O-GlcNAcylation is an important post-translational modification that is crucial for the function and localization of proteins, with the Golgi apparatus serving as an important subcellular compartment involved in O-GlcNAcylation-related protein regulation. However, the regulatory effects of FZ on the Golgi apparatus and O-GlcNAcylation remain unclear. Here, we found that FZ significantly reduces the viability, proliferative capacity, invasiveness, and metastatic potential of ovarian cancer cells while promoting apoptosis. In vivo, FZ decreases the formation of ascites in mice and diminishes peritoneal metastatic implantation without causing significant damage to major organs. Mechanistically, FZ disrupts the morphology and function of the Golgi apparatus, inhibits the O-GlcNAcylation of β-catenin, and promotes competitive phosphorylation of β-catenin, thereby preventing its translocation to the nucleus and ultimately inhibiting the invasion and metastasis of ovarian cancer. In summary, this study reveals that FZ disrupts the Golgi apparatus and inhibits the O-GlcNAcylation and nuclear translocation of β-catenin, thereby preventing the invasion and metastasis of ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
- Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. Electronic address: dr_hongli@whu.edu.cn.
- Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China. Electronic address: 2013103020057@whu.edu.cn.
Zitieren
APA
Peng, J., Liu, J., Ning, M., Han, W., Wang, H., Wang, Z., Hong, L., & Liu, C. (2025). Fluzoparib disrupts Golgi apparatus to inhibit O-GlcNAcylation and nuclear translocation of β-catenin to attenuate ovarian cancer invasion and metastasis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115158
Vancouver
Peng J, Liu J, Ning M, Han W, Wang H, Wang Z, et al. Fluzoparib disrupts Golgi apparatus to inhibit O-GlcNAcylation and nuclear translocation of β-catenin to attenuate ovarian cancer invasion and metastasis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115158
BibTeX
@article{Peng2025,
author = {Peng, Jiaxin and Liu, Jingchun and Ning, Minqi and Han, Wuyue and Wang, Haoyu and Wang, Zhi and Hong, Li and Liu, Cheng},
title = {Fluzoparib disrupts Golgi apparatus to inhibit O-GlcNAcylation and nuclear translocation of β-catenin to attenuate ovarian cancer invasion and metastasis},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115158}
}
EUVIMED